- Risankizumab is associated with better efficacy and similar safety compared with secukinumab for moderate to severe plaque psoriasis.
- These results are from to a 52-week, phase 3, randomized, open-label, efficacy assessor-blinded clinical trial.
Why this matters
- The availability of novel psoriasis treatments necessitates head-to-head trials.
- Risankizumab requires less frequent dosing compared with secukinumab.
- At week 16, risankizumab was noninferior to secukinumab for rates of ≥90% improvement in the Psoriasis Area Severity Index (PASI 90): 73.8% vs 65.6%.
- At 52 weeks, risankizumab was associated with a superior PASI 90 rate compared with secukinumab: 86.6% vs 57.1% (P<.001 style="list-style-type:circle;">
- Risankizumab was also superior for rates of PASI 75, PASI 100, and a static Physician Global Assessment score of 0 or 1 (P<.001 for all>
- 327 patients with chronic, moderate to severe plaque psoriasis were randomly assigned to receive risankizumab 150 mg (n=164) or secukinumab 300 mg (n=163), and efficacy and safety were assessed over 52 weeks.
- Funding: AbbVie.
- Open-label design.